Amphastar Pharmaceuticals Inc vs VanEck Australian Floating Rate ETF — how do they compare? Amphastar Pharmaceuticals Inc trades at $20.39 (market cap $863.95M), while VanEck Australian Floating Rate ETF trades at $50.93. The key difference: VanEck Australian Floating Rate ETF is trading nearer its 52-week high, Amphastar Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| AMPH | FLOT | |
|---|---|---|
Market Cap | $863.95M | — |
Sector | Health | Sector/Thematic |
52-Week High | $30.81 | $51.09 |
52-Week Low | $16.87 | $50.72 |
Enterprise Value | $1.26B | — |
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $20.78, up 4.9% today, with a bullish technical signal supported by moving averages. The stock shows mixed earnings performance with Q2 2026 beating estimates but Q1 and Q4 2025 missing. Fundamentals remain solid with a 10.76% net margin and reasonable valuation at 12.02 P/E. Recent news highlights Q2 2026 results and strategic shift toward proprietary drugs.
Outlook is cautiously optimistic with growth supported by new product launches, though regulatory risks and earnings volatility pose challenges. Analyst sentiment is mixed with 25% buy ratings but majority hold recommendations. The stock offers value but requires monitoring of FDA developments and earnings consistency.
FLOT, the iShares Floating Rate Bond ETF, trades at $50.93, showing minimal daily movement. The technical outlook is bearish based on moving averages, though oscillators are neutral. Recent news highlights its role as a potential hedge against rising interest rates, with a focus on high credit quality and a 4.0% SEC yield. Dividend payments are consistent, with recent distributions around $0.17-$0.18 per share.
The outlook for FLOT is cautiously positive if the Federal Reserve raises rates, as its floating rate structure could benefit income growth. Risks include credit quality deterioration and persistent inflation without Fed action. Analyst sentiment is generally neutral, viewing it as a stable short-term cash alternative rather than a growth vehicle.
Trailing returns across standard periods
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →FLOT provides exposure to a diversified portfolio of Australian dollar-denominated floating rate notes. It tracks the Bloomberg AusBond Credit FRN 0+ Yr Index, focusing on high-quality, investment-grade bonds from top Australian banks and financial institutions.
Read more on FLOT →